

Disclosures

Personal Commercial (0)

No disclosures on record

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (6)

| Trial Name | Trial Sponsor | Trial Funding Source |
|---|------------------------------|----------------------|
| DepleTTR-CM trial: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Deleter ALXN2220 in Adult Participants with ATTR-CM | Alexion Pharmaceuticals, Inc | |
| REDEFINE-HF: RandomizEd trial to DEtermine the efficacy and safety of FINErenone on morbidity and mortality among HF patients with LVEF>=40% hospitalized due to an episode of acute decompensated HF | CPC Clinical Research | |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRIBUTE-CM Trial) | Eidos | |
| MAGNITUDE: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants with ATTR-CM | Intellia Therapeutics, Inc. | |
| CardioTransform Study: A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with ATTR-CM | Ionis | |
| ACES-EMB. A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance with Cell-free DNA vs. Endomyocardial Biopsy. | Natera Inc. | |

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 2/15/2026

[URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement](http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement)

Confidentiality, Disclosure and Assignment Agreement | Signed on 2/15/2026

[URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement](http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement)

Embargo | Signed on 2/15/2026

[URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement](http://disclosures.acc.org/Public/Definition/EmbargoAgreement)

On-Going Obligation Agreement | Signed on 2/15/2026

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.

